Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings is taking strategic measures to increase operational control and earnings visibility by potentially acquiring a Contract Research Organization (CRO). If the acquisition is successful, Tevogen could cut costs and improve timelines in its T cell therapy pipeline while also generating additional revenue through external services. While the transaction is not guaranteed, it aligns with Tevogen's goal of implementing efficient growth strategies.

Bears say

Tevogen Bio Holdings is facing significant risks in both the short and long term, including reverse stock splits that disrupt shareholder base and lack of institutional investment following the split. The company's reliance on dilution as a means of financing and the recent decline in share price increases the overall dilution risk. Additionally, the delay in commercialization and uncertainties surrounding partnerships, financials, and legal matters pose further concerns about the company's prospects. These factors, combined with uncertainties in the market and the company's ambitious plans to build an integrated healthcare enterprise, contribute to our negative outlook on Tevogen Bio Holdings' stock.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.